Noctura Hero
Open For Investment

Untitled

EIS Eligible Investment Opportunity

PolyPhotonix Limited ("Noctura") is a pioneering MedTech business specialising in the design, development, and manufacturing of non-invasive, medical devices to treat diabetic eye disease. 

Driven by innovation and clinical need, PolyPhotonix is on a mission to enhance the lives of many diabetic patients suffering with eye disease.

Login or register for further detail

Firstname Lastname & Firstname Lastname

Position & Position, Company

Overview

A transformational MedTech business saving people's eyesight with a proven treatment for diabetic eye disease.

537 million adults worldwide are living with diabetes, with 153 million affected by diabetic eye disease (diabetic retinopathy). If untreated or undiagnosed, diabetic eye disease can lead to permanent blindness. Current treatments are invasive, costly, and inaccessible to many sufferers.

PolyPhotonix has created the Noctura 400 sleep mask, a Class IIa medical device approved for the treatment of diabetic retinopathy.

Noctura 400 is a non-surgical, non-invasive, home-based therapy designed to treat and prevent diabetic eye disease - a leading cause of vision loss worldwide.

  • How It Works: The sleep mask emits a gentle, low-level light to reduce oxygen demand in the eye, preventing hypoxia, a key factor in diabetic eye disease.
  • Patient-Centred Convenience: Unlike traditional treatments, Noctura 400 can be used at home, eliminating waiting lists and clinic visits.
  • Regulatory Assurance: The CE-marked, MHRA-registered medical device meets stringent UK and EU health, safety, and environmental standards.
  • Clinically Backed: Evaluated by the NHS, the Noctura 400 has demonstrated proven safety and efficacy in preventing and treating diabetic eye disease.

By redefining diabetic eye care, Noctura is delivering a scalable, cost-effective solution with the potential to transform patient outcomes worldwide.

Investment Opportunity

Noctura (PolyPhotonix Limited)

Target Sought: £ 1,999,950
Round: Round 1
Investment Type: Equity
Tax Schemes: EIS
Login or register to invest

The Team

Executive Team with a proven track record

Richard Kirk Founder & CEO
Professor Carlos Pavesio CSO
Martin Holland Operations Director
Ralph Pickles Chairman
John Brooks III Board Member

Noctura has regulatory approval for 33% of global diabetic retinopathy sufferers.  

Highlights

Key Investment Highlights

A snapshot of the Key Investment Highlights associated with Noctura and their EIS-eligible investment opportunity.

Numbers-01
EXPERIENCED
TEAM

An experienced leadership team and an advisory board of leading experts in ophthalmology from around the globe.

Numbers-02
INNOVATIVE
PRODUCT

The sleep mask emits a gentle, low-level light to reduce oxygen demand in the eye, preventing hypoxia, a key factor in diabetic eye disease.

Numbers-03
DEFENSIBLE
IP

Four filed and registered patents in place, providing significant value to the Company.

Numbers-04
ACQUISITION OPPORTUNITY 

The Noctura sleep mask product complements the diabetic treatments of major pharmaceutical companies, meaning the Company could be a prime target for a strategic acquisition.

Numbers-05
VAST MARKET
OPPORTUNITY 

With 153 million sufferers of diabetic eye disease worldwide, Noctura already has regulatory approval for 33% of the global patient population.

Numbers-06
BETTER THAN
ALTERNATIVES

A non-invasive therapy that can be administered much earlier than alternative treatments, which are often highly invasive and costly.

Numbers-07
IMPACT-DRIVEN
INVESTMENT

Funding a business dedicated to improving the quality of life for people worldwide.

Numbers-08
TARGET 
RETURNS

Target returns of 9.52x. Your capital is at risk and target returns are not guaranteed.

Open For Investment

Untitled

EIS Eligible Investment Opportunity
Download the marketing materials to discover the full details of the current investment opportunity into Noctura.

DOWNLOAD THE MARKETING MATERIALS
noctura brochure

Start

  • Since Inception - PolyPhotonix receive over £20m in funding and grants to support a rigorous research and development programme, advance product development and clinical trials, strengthen intellectual property through a solid suite of patents, and execute its initial go-to-market strategy.

  • 2022 - A study by Ulrich Meyer-Bothling showed that 94% of all patients who correctly used the mask showed significant stabilisation and sometimes even improvement of the central diabetic maculopathy and vision with some patients seeing a reverse of their condition.

  • 2023 - PolyPhotonix Limited signs a co-promotional agreement with embecta, allowing the promotion of the Noctura sleep mask to healthcare professionals within the UK and Ireland.

  • 2024 - Noctura launches their e-commerce website allowing customers to purchase the sleep mask either as a one-time purchase or through a subscription plan.

  • 2025 - £2m investment round launches to accelerate the go-to-market strategy. Funds will be used to drive continued growth across the e-commerce website and strengthen marketing strategies.

s300_TSB31032014_36_polyphotonix1

Now

FAQs

Want to find out more about investing with GCV?

Should you have any further questions regarding this investment opportunity, please reach to the Investment Team, you can contact us at any point 

  • Contact Millie Haigh - Investor Relations Director - millie.gerber@growthcapitalventures.co.uk

  • There are no joinings fees. Membership of GCV Invest is completely free, giving you access to well researched, carefully selected investment opportunities across asset classes, all with the potential to provide portfolio diversification and superior investment returns.

    Transaction fees are only charged at the point of a liquidity event occurring (such as a trade sale or IPO for private companies and completion of a residential development for property transactions). At this point, 7.5% of the investment gain is charged before funds are provided back to you as an investor.

    Whilst dividend payments should not be expected from early-stage companies, more mature companies may include dividend payments, if and when they are paid, 7.5% of the dividend amount is charged to investors.

  • Where a wide range of information on tax efficient investing is readily available at the touch of a button, ensuring sources are up to date, unbiased and accurate can be a crucial task when researching the ever-evolving tax efficient investing landscape  - why not try the GCV Invest content library as a starting point?

  • GCV offer experienced investors the opportunity to invest in carefully researched early-stage businesses with high growth potential.

     

    We specialise in opportunities that are SEIS and EIS qualifying, offering investors generous income tax reliefs of between 30% and 50% when making the investment and no capital gains tax on investment profits at realisation stage.

Don't invest unless you're prepared to lose all the money you invest. This is a high-risk investment and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more
Risk Summary

Estimated reading time: 2 min

Due to the potential for losses, the Financial Conduct Authority (FCA) considers this investment to be high risk.

What are the key risks?

  • You could lose all the money you invest
  • Most investments are shares in start-up businesses or bonds issued by them. Investors in these shares or bonds often lose 100% of the money they invested, as most start-up businesses fail.
  • Checks on the businesses you are investing in, such as how well they are expected to perform, may not have been carried out by the platform you are investing through. You should do your own research before investing.

You won't get your money back quickly

  • Even if the business you invest in is successful, it will likely take several years to get your money back.
  • The most likely way to get your money back is if the business is bought by another business or lists its shares on an exchange such as the London Stock Exchange. These events are not common.
  • Start-up businesses very rarely pay you back through dividends. You should not expect to get your money back this way.
  • Some platforms may give you the opportunity to sell your investment early through a 'secondary market' or 'bulletin board', but there is no guarantee you will find a buyer at the price you are willing to sell.

Don't put all your eggs in one basket

  • Putting all your money into a single business or type of investment for example, is risky. Spreading your money across different investments makes you less dependent on any one to do well. A good rule of thumb is not to invest more than 10% of your money in high-risk investments. Learn more here.

The value of your investment can be reduced

  • If your investment is shares, the percentage of the business that you own will decrease if the business issues more shares. This could mean that the value of your investment reduces, depending on how much the business grows. Most start-up businesses issue multiple rounds of shares.
  • These new shares could have additional rights that your shares don't have, such as the right to receive a fixed dividend, which could further reduce your chances of getting a return on your investment.

You are unlikely to be protected if something goes wrong

  • Protection from the Financial Services Compensation Scheme (FSCS), in relation to claims against failed regulated firms, does not cover poor investment performance. Try the FSCS investment protection checker.
  • Protection from the Financial Ombudsman Service (FOS) does not cover poor investment performance. If you have a complaint against an FCA-regulated platform, FOS may be able to consider it. Learn more about FOS protection here.

If you are interested in learning more about how to protect yourself, visit the FCA's website here.

For further information about investment-based crowdfunding, visit the crowdfunding section of the FCA's website here.
Driving Growth.
Creating Value.
Delivering Impact.

Backed by

Growth Capital Ventures (GCV) is backed by funds managed by Maven Capital Partners, one of the UK’s leading private equity and alternative asset managers.